Aytu Biopharma (AYTU) Share-based Compensation (2014 - 2026)

Aytu Biopharma (AYTU) has 13 years of Share-based Compensation data on file, last reported at $148000.0 in Q1 2026.

• On a quarterly basis, Share-based Compensation changed N/A year-over-year to $148000.0 in Q1 2026; TTM through Mar 2026 was $658000.0, a 2.66% decrease from a year earlier, with the FY2025 full-year figure at $576000.0, down 80.23% from the prior year.
• Share-based Compensation for Q1 2026 stood at $148000.0, down from $283000.0 in the prior quarter.
• Over the last five years, Share-based Compensation for AYTU reached as high as $3.1 million in Q4 2022 and fell as low as $113000.0 in Q2 2025.
• Historically, Share-based Compensation has averaged $777562.5 across 5 years, with a median of $815500.0 in 2023.
• Across the five-year window, Share-based Compensation surged 149.55% in 2022 and slumped 81.59% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $3.1 million in 2022, then plunged by 73.26% to $820000.0 in 2023, then slumped by 81.59% to $151000.0 in 2024, then soared by 87.42% to $283000.0 in 2025, then tumbled by 47.7% to $148000.0 in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $148000.0 in Q1 2026, $283000.0 in Q4 2025, and $114000.0 in Q3 2025.